January/February 2017

Having the right evidence, using high-value care, and developing strong incentives to improve payment and delivery systems are among the ways we can improve healthcare.

This analytic model assessed the per-woman cost differences between the use of 2 levonorgestrel-releasing intrauterine devices, from a US payer perspective.

The characteristics of patients who require increases in their basal insulin dose were compared with those requiring no increase following conversion between basal insulin analogues.

Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).

In our quest to identify the areas and activities that show the greatest positive impact and value in care and outcomes, we must aim to not let good science and evidence get away from us, particularly when considering vaccination.